Neurocrine Biosciences reported $779.7M in Operating Expenses for its fiscal quarter ending in September of 2026.





Operating Expenses Change Date
AbbVie USD 10.52B 258M Sep/2026
Acadia Pharmaceuticals USD 270.57M 450K Sep/2026
Agios Pharmaceuticals USD 155.3M 24.53M Jun/2026
ALKERMES USD 1.86B 56.17M Sep/2026
Alnylam Pharmaceuticals USD 1.11B 52.78M Sep/2026
Amgen USD 5.69B 6B Sep/2026
Biogen USD 2.32B 663.6M Sep/2026
BioMarin Pharmaceutical USD 819.04M 5.5B Sep/2026
Cytokinetics USD 214.64M 6.85M Sep/2026
Enanta Pharmaceuticals USD 126.59M 346.51M Dec/2025
Exelixis USD 390.27M 10M Sep/2026
Gilead Sciences USD 13.04B 9.09B Sep/2026
Halozyme Therapeutics USD 198M 4.66M Sep/2026
Incyte USD 5.64B 4.67B Sep/2026
Ionis Pharmaceuticals USD 373M 2.76M Sep/2026
Nektar Therapeutics USD 49.12M 8.22M Mar/2026
Neurocrine Biosciences USD 779.7M 40.6M Sep/2026
Pfizer USD 89B 3.81B Sep/2026
Prothena USD 19.7M 5.6M Jun/2026
Regeneron Pharmaceuticals USD 33.5B 1.79B Sep/2026
Repligen USD 185.01M 2.01M Sep/2026
Rigel Pharmaceuticals USD 117.61M 35.67M Sep/2025
Sarepta Therapeutics USD 390.39M 2.43M Sep/2026
Teva Pharmaceutical Industries USD 3.18B 733M Sep/2026
Ultragenyx Pharmaceutical USD 283M 6M Sep/2026
Vertex Pharmaceuticals USD 2.18B 118.2M Sep/2026